drugset / Trial / NCT07712094
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a single prospective, parallel, double-cohort, multicenter phase II clinical trial, aiming to evaluate the efficacy and safety of ivonescimab (AK112) combined with IP chemotherapy ± TACE in the first-line treatment of metastatic digestive system neuroendocrine cancer.
Timeline
- Start
- 2026-08-01
- Primary completion
- 2029-02-27
- Completion
- 2029-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 30 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 65 mg/m2 | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | 20 mg/kg | Intravenous |